In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care investigated whether nivolumab has an added benefit over watchful waiting in the adjuvant treatment of adults with carcinoma of the esophagus or the gastroesophageal junction and pathological residual disease after prior neoadjuvant chemoradiotherapy (CRT).
from News Medical Medical Research News Feed https://ift.tt/31HWzbk
0 Comments